Vaccines against avian reoviruses
The present invention relates to vaccine and composition comprising at least one antigenic material derived from an avian reovirus and an adjuvant comprising a lipophile and a polymer of acrylic or methacrylic acid and uses thereof for vaccinating avian against reoviruses.
1. A vaccine comprising at least one antigenic material derived from an avian reovirus selected from avian reovirus designated strain S1, a sample of which is deposited at the ATCC under accession number PTA-125155 (S1), avian reovirus designated strain S2, a sample of which is deposited at the ATCC under accession number PTA-125157 (S2), avian reovirus designated strain S3, a sample of which is deposited at the ATCC under accession number PTA-125156 (S3), or any derivative thereof and an adjuvant comprising a lipophile and a polymer of acrylic or methacrylic acid.
2. The vaccine of claim 1 , wherein the polymer of acrylic or methacrylic acid is a carbomer.
3. The vaccine of claim 1 , wherein the lipophile is selected from the group consisting of medium chain EP triglycerides, medium chain triglycerides NF, medium chain fatty acid triglyceride JPE, caprylic/capric triglyceride, and combinations thereof.
4. The vaccine of claim 1 , wherein the adjuvant further comprises at least one compound selected from saline, sterol, alcohol, saponin, sodium hydroxide, and any combination thereof.
5. The vaccine of claim 1 , wherein the antigenic material comprises an inactivated avian reovirus.
6. The vaccine of claim 1 , comprising antigenic materials derived from at least two distinct avian reovirus strains.
7. The vaccine of claim 1 , wherein the antigenic material is derived from at least two reoviruses selected from strain S1, strain S2 and strain S3, or any derivative thereof.
8. The vaccine of claim 1 , wherein the antigenic material is derived from strain SI, strain S2 and strain S3, which are present in similar amounts.
9. The vaccine of claim 1 , wherein the vaccine comprises from 10 3 TCID 50 /dose to 10 9 TCID 50 /dose of the at least one avian reovirus antigenic material.
10. The vaccine of claim 1 , wherein the vaccine comprises from 10 3 TCID 50 /dose to 10 9 TCID 50 /dose of an inactivated avian reovirus selected from strain S1, strain S2, and strain S3.
11. The vaccine of claim 1 , wherein the vaccine comprises additional antigenic material from a distinct avian pathogen.
12. The vaccine of claim 1 , further comprising a pharmaceutically acceptable carrier.
13. A vaccine comprising at least one antigenic material derived from an avian reovirus selected from avian reovirus designated strain S1, a sample of which is deposited at the ATCC under accession number PTA-125155 (S1), avian reovirus designated strain S2, a sample of which is deposited at the ATCC under accession number PTA-125157 (S2), avian reovirus designated strain S3, a sample of which is deposited at the ATCC under accession number PTA-125156 (S3), and an adjuvant.
14. A process for preparing a vaccine comprising at least one antigenic material derived from an avian reovirus selected from avian reovirus designated strain S1, a sample of which is deposited at the ATCC under accession number PTA-125155 (S1), avian reovirus designated strain S2, a sample of which is deposited at the ATCC under accession number PTA-125157 (S2), avian reovirus designated strain S3, a sample of which is deposited at the ATCC under accession number PTA-125156 (S3), and an adjuvant, comprising
preparing the at least one antigenic material; and
adding an adjuvant comprising a lipophile and a polymer of acrylic or methacrylic acid.
15. The process of claim 14 , further comprising a step of
homogenously mixing the at least one antigenic material with glycine and thimerosal solutions, before adding the adjuvant.
16. A method for vaccinating an avian against reovirus, comprising administering to the avian a vaccine of claim 1 .